Evidence map›Paper›PMID 42142288›Full record

ArticleCurrent microbiology2026

Whole Genome Analysis of Propiconazole-Degrading Serratia marcescens BM-Q: A Rhizobacterium.

Maha Binte Masood, Muhammad Nadeem Hassan

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maha Binte MasoodDepartment of Biosciences, COMSATS University Islamabad (CUI), Islamabad Campus, Park Road, Islamabad (45550), Pakistan.
Muhammad Nadeem HassanDepartment of Biosciences, COMSATS University Islamabad (CUI), Islamabad Campus, Park Road, Islamabad (45550), Pakistan. nadeem_hassan@comsats.edu.pk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irrational application of propiconazole in agriculture poses serious environmental concerns due to its toxicity and persistence in soil. This study investigates the degradation potential of Serratia marcescens strain BM-Q and explores the key pathways involved in the degradation process through annotation and comparative analysis of whole genome. Strain BM-Q exhibited high tolerance to propiconazole (3000 µg/mL) and a decline in total soluble protein was observed in BM-Q under propiconazole stress, decreasing from 101.16 µg mL⁻¹ in the control to 41.53 µg mL⁻¹ at the 25× concentration. Gas chromatography analysis revealed that the concentration of propiconazole decreased from 100 mg/kg at day 0 to 69.06 mg/kg within 40 days, corresponding to 30.94% degradation by BM-Q, with a rate constant of 0.009 day⁻¹ and a half-life of 79.70 days. Whole genome sequencing indicated that the strain BM-Q harbors a 5.19 Mbp genome with 59.62% G + C content and 4,977 annotated genes, of which 178 are unique when compared with reference S. marcescens strains exhibiting potential to degrade various pesticides and hydrocarbons. Comparative genomic analysis results showed an average nucleotide identity of 99.32% with the S. marcescens strain MEW06. Genomic pathway analysis revealed that Serratia marcescens BM-Q harbors an extensive repertoire of catabolic genes involved in the degradation of diverse aromatic and xenobiotic compounds, indicating strong ecological adaptation and robust bioremediation potential. Strain BM-Q therefore exhibits low virulence potential and can be considered a non-pathogenic, low-risk candidate for environmental bioremediation. Our findings indicate that BM-Q can be a promising candidate for bioremediation of propiconazole-contaminated environments.

Indexed as

Genome, BacterialSerratia marcescensTriazolesBase CompositionBiodegradation, EnvironmentalSoil PollutantsWhole Genome SequencingpropiconazoleSoil PollutantsTriazoles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.